vs
Side-by-side financial comparison of Origin Bancorp, Inc. (OBK) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Origin Bancorp, Inc. is the larger business by last-quarter revenue ($104.0M vs $92.9M, roughly 1.1× Vericel Corp). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs 25.0%, a 1.6% gap on every dollar of revenue. Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 3.9%).
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
OBK vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.0M | $92.9M |
| Net Profit | $27.7M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 26.6% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $0.89 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.0M | — | ||
| Q4 25 | $103.4M | $92.9M | ||
| Q3 25 | $109.8M | $67.5M | ||
| Q2 25 | $83.5M | $63.2M | ||
| Q1 25 | $94.1M | $52.6M | ||
| Q4 24 | $78.3M | $75.4M | ||
| Q3 24 | $90.8M | $57.9M | ||
| Q2 24 | $96.4M | $52.7M |
| Q1 26 | $27.7M | — | ||
| Q4 25 | $29.5M | $23.2M | ||
| Q3 25 | $8.6M | $5.1M | ||
| Q2 25 | $14.6M | $-553.0K | ||
| Q1 25 | $22.4M | $-11.2M | ||
| Q4 24 | $14.3M | $19.8M | ||
| Q3 24 | $18.6M | $-901.0K | ||
| Q2 24 | $21.0M | $-4.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | 36.2% | 24.1% | ||
| Q3 25 | 10.0% | 5.1% | ||
| Q2 25 | 22.3% | -3.2% | ||
| Q1 25 | 30.4% | -24.3% | ||
| Q4 24 | 23.0% | 24.5% | ||
| Q3 24 | 26.1% | -4.3% | ||
| Q2 24 | 27.7% | -11.5% |
| Q1 26 | 26.6% | — | ||
| Q4 25 | 28.5% | 25.0% | ||
| Q3 25 | 7.9% | 7.5% | ||
| Q2 25 | 17.5% | -0.9% | ||
| Q1 25 | 23.8% | -21.4% | ||
| Q4 24 | 18.2% | 26.3% | ||
| Q3 24 | 20.5% | -1.6% | ||
| Q2 24 | 21.8% | -8.9% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.95 | $0.46 | ||
| Q3 25 | $0.27 | $0.10 | ||
| Q2 25 | $0.47 | $-0.01 | ||
| Q1 25 | $0.71 | $-0.23 | ||
| Q4 24 | $0.45 | $0.40 | ||
| Q3 24 | $0.60 | $-0.02 | ||
| Q2 24 | $0.67 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $354.6M |
| Total Assets | $10.2B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $424.2M | $137.5M | ||
| Q3 25 | $626.9M | $135.4M | ||
| Q2 25 | $334.1M | $116.9M | ||
| Q1 25 | $486.2M | $112.9M | ||
| Q4 24 | $470.2M | $116.2M | ||
| Q3 24 | $321.2M | $101.7M | ||
| Q2 24 | $288.1M | $102.5M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $354.6M | ||
| Q3 25 | $1.2B | $321.9M | ||
| Q2 25 | $1.2B | $306.8M | ||
| Q1 25 | $1.2B | $295.5M | ||
| Q4 24 | $1.1B | $292.0M | ||
| Q3 24 | $1.1B | $257.5M | ||
| Q2 24 | $1.1B | $243.0M |
| Q1 26 | $10.2B | — | ||
| Q4 25 | $9.7B | $488.0M | ||
| Q3 25 | $9.8B | $453.3M | ||
| Q2 25 | $9.7B | $435.6M | ||
| Q1 25 | $9.8B | $424.6M | ||
| Q4 24 | $9.7B | $432.7M | ||
| Q3 24 | $10.0B | $390.4M | ||
| Q2 24 | $9.9B | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $158.9M | $15.0M | ||
| Q3 25 | $59.3M | $22.1M | ||
| Q2 25 | $20.6M | $8.2M | ||
| Q1 25 | $35.6M | $6.6M | ||
| Q4 24 | $108.5M | $22.2M | ||
| Q3 24 | $39.6M | $10.2M | ||
| Q2 24 | $11.9M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | $151.1M | $12.8M | ||
| Q3 25 | $56.8M | $19.5M | ||
| Q2 25 | $19.6M | $81.0K | ||
| Q1 25 | $34.8M | $-7.6M | ||
| Q4 24 | $86.4M | $8.5M | ||
| Q3 24 | $32.2M | $-9.2M | ||
| Q2 24 | $6.5M | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 146.0% | 13.8% | ||
| Q3 25 | 51.7% | 28.8% | ||
| Q2 25 | 23.5% | 0.1% | ||
| Q1 25 | 37.0% | -14.5% | ||
| Q4 24 | 110.3% | 11.2% | ||
| Q3 24 | 35.5% | -15.9% | ||
| Q2 24 | 6.8% | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 2.4% | ||
| Q3 25 | 2.3% | 3.9% | ||
| Q2 25 | 1.2% | 12.9% | ||
| Q1 25 | 0.8% | 27.0% | ||
| Q4 24 | 28.1% | 18.3% | ||
| Q3 24 | 8.1% | 33.5% | ||
| Q2 24 | 5.6% | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | 5.38× | 0.65× | ||
| Q3 25 | 6.88× | 4.35× | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | 7.60× | 1.12× | ||
| Q3 24 | 2.13× | — | ||
| Q2 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
